This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Eurneffy, epinephrine,...
Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide,...
Human medicines European public assessment report (EPAR): Epruvy (previously Ran...
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Pro...
Guideline on quality, non-clinical and clinical requirements for investigational...
Training on human variations web-based electronic application form (eAF) functio...
EMA human resources strategy: Priorities 2023-2025
Product Management Service (PMS) webinar on Product User Interface (PUI) edit fu...
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of ...
Questions and answers clinic on Product Management Service (PMS) Product User In...
List of medicines currently in PRIME scheme
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, ...
Human medicines European public assessment report (EPAR): Datroway, datopotamab ...
EMA Open Door Day, European Medicines Agency, Amsterdam, the Netherlands, from 9...
Human medicines European public assessment report (EPAR): Stivarga, regorafenib,...
Elected leaders in Massachusetts said the NIH policy change will interrupt cruci...
National Institutes of Health slashed overhead costs allowed under its grants to...
After two decades of work in biomedical research policy, there is no topic Carri...
The drastic reduction in indirect costs is not a path to innovation or cost savi...
The NIH said Friday night that it would slash support for indirect costs on all ...